Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on prostate cancer active surveillance.
The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was ...
News-Medical.Net on MSN13d
Groundbreaking scanner could revolutionize breast cancer diagnosis and treatmentA groundbreaking new scanner developed by scientists at the University of Aberdeen could change the way breast cancer is ...
Multiparametric magnetic resonance imaging (MRI)-based machine learning techniques have the potential to identify B-cell lymphoma-6 (BCL-6) overexpression in patients with primary central nervous ...
The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...
The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...
MRI should be considered an adjunct to, and not a replacement for, biopsies for men on active surveillance for prostate cancer. MRI does not consistently rule out the presence of Gleason grade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback